A Phase III trial evaluating Dupixent (dupilumab) in adults with uncontrolled prurigo nodularis has met its primary and all key secondary endpoints. 22 October 2021
French drugmaker Sanofi has announced that the Phase III PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not me 9 September 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.